Medical management of myocardial infarction.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D001243:Assisted Circulation; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010102:Oxygen Inhalation Therapy; D010138:Pacemaker, Artificial; D014294:Trimethaphan / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D004071:Digitalis Glycosides; D009599:Nitroprusside; D014294:Trimethaphan; D005665:Furosemide; D005934:Glucagon; D005996:Nitroglycerin; D004976:Ethacrynic Acid